MA51587B1 - Conjugués oligomère de sauts d'exons pour la dystrophie musculaire - Google Patents

Conjugués oligomère de sauts d'exons pour la dystrophie musculaire

Info

Publication number
MA51587B1
MA51587B1 MA51587A MA51587A MA51587B1 MA 51587 B1 MA51587 B1 MA 51587B1 MA 51587 A MA51587 A MA 51587A MA 51587 A MA51587 A MA 51587A MA 51587 B1 MA51587 B1 MA 51587B1
Authority
MA
Morocco
Prior art keywords
oligomer conjugates
muscular dystrophy
exon skipping
skipping oligomer
exon
Prior art date
Application number
MA51587A
Other languages
English (en)
Other versions
MA51587A (fr
Inventor
Gunnar J Hanson
Marco A Passini
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066222 external-priority patent/WO2018118599A1/fr
Publication of MA51587A publication Critical patent/MA51587A/fr
Publication of MA51587B1 publication Critical patent/MA51587B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Des conjugués oligomère antisens capables de se lier à un site cible sélectionné du gène de la dystrophine humaine pour induire le saut de l'exon 51 sont décrites.
MA51587A 2016-12-19 2017-12-13 Conjugués oligomère de sauts d'exons pour la dystrophie musculaire MA51587B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436182P 2016-12-19 2016-12-19
PCT/US2017/066222 WO2018118599A1 (fr) 2016-12-19 2017-12-13 Conjugués oligomère de sauts d'exons pour la dystrophie musculaire

Publications (2)

Publication Number Publication Date
MA51587A MA51587A (fr) 2019-10-23
MA51587B1 true MA51587B1 (fr) 2022-09-30

Family

ID=65895706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51587A MA51587B1 (fr) 2016-12-19 2017-12-13 Conjugués oligomère de sauts d'exons pour la dystrophie musculaire

Country Status (2)

Country Link
AR (1) AR110389A1 (fr)
MA (1) MA51587B1 (fr)

Also Published As

Publication number Publication date
MA51587A (fr) 2019-10-23
AR110389A1 (es) 2019-03-27

Similar Documents

Publication Publication Date Title
MA65895B1 (fr) Conjugués d'oligomères induisant le saut d'exons pour la dystrophie musculaire
MA45618A (fr) Sauts d'exons oligomères pour la dystrophie musculaire
EA201991450A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MX2019006882A (es) Conjugados de oligomeros de omision de exon para distrofia muscular.
CY1121876T1 (el) Συνθεσεις παρακαμψης εξωνιου για τη θεραπεια της μυϊκης δυστροφiας
MY205772A (en) Exon skipping oligomer conjugates for muscular dystrophy
IL268856A (en) Methods for purification of messenger rna
IL271389A (en) Targeted non-viral dna insertions
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
EP3463483A4 (fr) Traitement de dyskinésie ciliaire primaire à l'aide d'arn messager de synthèse
EP3463290A4 (fr) Régulation à contre-réaction du vih-1 par une stratégie d'édition génique
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
WO2019241385A3 (fr) Oligomères induisant un saut d'exon pour la dystrophie musculaire
EA202092772A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3347466A4 (fr) Détermination du nombre de copies génétiques au moyen d'un séquençage multiplex à haut débit de nucléotides smash
EP3344650A4 (fr) Aav-epo pour le traitement d'animaux de compagnie
EP3673505A4 (fr) Ensemble d'injection pour des processus de dépôt épitaxial
EP3367784A4 (fr) Ingénierie d'organes humanisés par complémentation génétique
EA202191601A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3693487A4 (fr) Acier inoxydable à base d'austénite
MA51582B1 (fr) Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
MA51587B1 (fr) Conjugués oligomère de sauts d'exons pour la dystrophie musculaire
MA47015B1 (fr) Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
EP3363464A4 (fr) Composition pharmaceutique pour le traitement du cancer comprenant un oligonucléotide d'arn
EP3311164A4 (fr) Méthodes et compositions pour le diagnostic et le pronostic de l'appendicite et la différenciation des causes de la douleur abdominale